How should chronic spontaneous urticaria be treated?

How to Treat Chronic Spontaneous Urticaria (CSU)

Start with standard-dose second-generation H1-antihistamines as first-line therapy, and if inadequate control persists after 2-4 weeks, increase the dose up to 4-fold before advancing to omalizumab. 1

Treatment Algorithm

Step 1: Second-Generation H1-Antihistamines (First-Line)

Begin with standard-dose second-generation H1-antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) taken once daily 1. These achieve complete control in approximately 40-50% of patients at standard doses 2, 3.

If symptoms remain intolerable or inadequate control after 2-4 weeks:

• Increase the antihistamine dose up to 4-fold 1
• This up-dosing is safe and increases response rates to approximately 63% 4
• Offer patients a choice of at least two different antihistamines, as individual responses vary 5

Critical pitfall: Avoid prolonged ineffective antihistamine therapy—do not continue standard or up-dosed antihistamines beyond 2-4 weeks if symptoms remain uncontrolled, as this delays disease control 3.

Step 2: Omalizumab (Second-Line)

If inadequate control persists despite up-dosed antihistamines:

• Add omalizumab 300 mg subcutaneously every 4 weeks 1
• This achieves complete disease control in approximately 70% of antihistamine-refractory patients 4
• Allow up to 6 months for patients to respond before declaring treatment failure 1

For insufficient response to standard omalizumab dosing:

• Consider dose escalation up to 600 mg every 2 weeks by shortening intervals and/or increasing dosage 1
• This is particularly beneficial in patients with high body mass index 1
• The safety profile of higher doses mirrors that of standard dosing 1

Important consideration: At least 30% of patients have insufficient response to omalizumab, especially those with IgG-mediated autoimmune CSU (Type IIb) 2, 6.

Step 3: Cyclosporine (Third-Line)

If inadequate control persists after 6 months of omalizumab (including up-dosing attempts):

• Add cyclosporine up to 5 mg/kg body weight daily 1
• Particularly effective in autoimmune CSU (Type IIb) with response rates of 54-73% 2
• Superior efficacy in omalizumab non-responders with IgG autoantibodies 6

Mandatory monitoring requirements:

• Check blood pressure and renal function (BUN and creatinine) every 6 weeks 1
• Be vigilant for hypertension, renal dysfunction, hirsutism, gum hypertrophy, and risk of seizures in predisposed patients 1

The risk-benefit profile of high-dose omalizumab is superior to cyclosporine, making exhaustive omalizumab optimization essential before advancing to cyclosporine 1.

Treatment Optimization Strategy

Step-Up and Step-Down Approach

The 2022 international guideline emphasizes an "as much as needed and as little as possible" approach 1:

When to step down:

• Only after achieving at least 3 consecutive months of complete disease control (Urticaria Control Test score >16) 1
• Reduce antihistamine dose by no more than 1 tablet per month 1
• If breakthrough symptoms occur, return to the last dose that provided complete control 1

Timing Considerations

• Assess response to standard-dose antihistamines: 2-4 weeks (or earlier if symptoms intolerable) 1
• Assess response to up-dosed antihistamines: 2-4 weeks (or earlier if symptoms intolerable) 1
• Assess response to omalizumab: up to 6 months (or earlier if symptoms intolerable) 1

Adjunctive Measures

Avoid or minimize aggravating factors:

• NSAIDs and aspirin (particularly in aspirin-sensitive patients) 5
• ACE inhibitors (especially if angioedema present) 5
• Alcohol, overheating, and stress 5

Symptomatic relief:

• Cooling antipruritic lotions (calamine or 1% menthol in aqueous cream) 5

Key Guideline Changes (2022 Update)

The most recent international urticaria guideline streamlined treatment from 4 steps to 3 clear steps, removing leukotriene receptor antagonists and first-generation antihistamines from the algorithm 1. This simplification reflects robust evidence supporting the current three-tier approach and emphasizes rapid escalation when lower tiers fail.

The algorithm prioritizes morbidity and quality of life outcomes by preventing prolonged periods of inadequate control through timely treatment escalation 1.